Trial Profile
A Study of the Comparative Bioavailability of Two Second-Generation Investigational Pediatric Oral Granule Formulations of MK-1439 Compared to the Adult Formulation. Additional PIP decision number: P/139/2016
Status:
Not stated
Phase of Trial:
Phase I
Latest Information Update: 22 Nov 2016
Price :
$35
*
At a glance
- Drugs Doravirine (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Acronyms MK-1439 Mini-Tab Study
- Sponsors Merck Sharp & Dohme
- 22 Nov 2016 New trial record